Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis

Rini Noviyani,Nathorn Chaiyakunapruk,Sitaporn Youngkong,Piyamitr Sritara,Bhavani Shankara Bagepally,Usa Chaikledkaew,Surakit Nathisuwan,John Attia,Gareth Mckay,Ammarin Thakkinstian

doi:10.1136/bmjebm-2020-111634

Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis

Rini Noviyani, Nathorn Chaiyakunapruk + Show 8 more

Open Access

https://doi.org/10.1136/bmjebm-2020-111634

Copy DOI

Journal: BMJ Evidence-Based Medicine	Publication Date: Oct 11, 2021
Citations: 13	License type: open-access

Affiliation: University of Utah, Mahidol University, Ramathibodi Hospital, National Institute of Epidemiology, University of Newcastle Australia, Queen's University Belfast, Udayana University

#Versus Vitamin K Antagonists #Incremental Net Benefits + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectivesTo assess cost-effectiveness of direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling incremental net benefits (INBs).DesignSystematic review and meta-analysis.SettingWe...

Full Text